BrightSpring Lifts 2026 Outlook As Quarterly Revenue Climbs 26.4% To $4.2 Billion

Net income from continuing operations reached $101 million, and leverage dropped to 1.79x from 2.15x at the end of June.

Share
BrightSpring Lifts 2026 Outlook As Quarterly Revenue Climbs 26.4% To $4.2 Billion

BrightSpring Health Services, which provides pharmacy and in-home care to medically complex patients, raised its full-year 2026 revenue and adjusted EBITDA guidance after third-quarter revenue rose 26.4% to $4,213 million, the company reported Friday. Net income from continuing operations came in at $101 million, against $38 million a year earlier.

Profit and margins outrun sales

Gross profit rose 32.3% to $519 million from $392 million in the third quarter of 2025. Adjusted EBITDA, a profit measure that strips out items such as stock pay and deal costs, climbed 42.0% to $228 million from $160 million.

All figures cover continuing operations. BrightSpring completed the sale of its Community Living business on March 30, 2026, according to the company's release.

CEO Jon Rousseau said the company has "a differentiated company" and that its confidence in the future "remains high."

Pharmacy volume flat, home health surges

Pharmacy Solutions revenue rose 26% to $3,732 million, and its segment EBITDA gained 43% to $202 million. Prescriptions dispensed edged up 2% to 10,949,875, so the growth came mostly from revenue per script, which rose 24% to $340.86.

Provider Services revenue rose 31% to $481 million, with segment EBITDA up 30% to $79 million. Home Health Care average daily census jumped 58% to 47,256 from 29,980. Rehab Care persons served rose 9% to 7,574, and Personal Care rose 1% to 16,320.

BrightSpring runs pharmacies delivering infusion and oncology specialty drugs alongside home health, hospice, rehab and personal care services, and reports in all 50 states.

New guidance and a lighter debt load

The company now expects 2026 revenue of $15,900 million to $16,125 million, or 23.2% to 24.9% growth, and adjusted EBITDA of $850 million to $860 million. The outlook excludes Community Living and any future closed acquisitions. The Amedisys and LHC branches acquisition is expected to add about $35 million of adjusted EBITDA in 2026.

Leverage stood at 1.79x on September 30, down from 2.15x on June 30. Cash was $717.8 million at quarter-end, up from $88.4 million at the end of 2025.

Management discussed the results on a call at 8:30 a.m. Eastern on Friday, with supplemental slides posted on its investor relations site.

Sources